NR1D1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-10. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Susie Orbach (born 6 November 1946), psychotherapist, psychoanalyst, writer and social critic; daughter of Maurice Orbach, author of Fat is a Feminist Issue, married to author Jeanette Winterson. She is honoured in BBC'S 100 Women in 2013 and 2014. She was the therapist to Diana, Princess of Wales during the 1990s. Yotam Ottolenghi (born 14 December 1968), Israeli-British celebrity chef; journalist for The Guardian and Haaretz; author of several cookery books, including Ottolenghi: The Cookbook (2008), Plenty (2010), Jerusalem (2012). Moved to Europe after his service in Military Intelligence Directorate (Israel); in 2014, London Evening Standard remarked that Ottolenghi had "radically rewritten the way Londoners cook and eat"; in 2017 was guest judge on Masterchef Australia. Ilan Pappé, pro-Palestinian dissident Israeli-British scholar, writer and author of Ashkenazi origin, focusing on the history of Palestinian Nakba, intifada, insurgency, land ownership and rights and radical Anti-Zionism. Joseph Pardo (c. 1624 – 1677), hazzan and writer David Patrikarakos; journalist and war correspondent, author of War in 140 Characters: How Social Media Is Reshaping Conflict in the Twenty-First Century; wrote Nuclear Iran: Birth of An Atomic State which was named as a New York Times Editor's Choice and nominated for Total Politics Book Awards. Ruthie Pearlman, Orthodox Jewish Crime Writer and writer of Young Adult Fiction.
=== Lactate dehydrogenase === Lactate dehydrogenase (LDH) is found in many body tissues, including the liver. Elevated levels of LDH may indicate liver damage. LDH isotype-1 (or cardiac) is used for estimating damage to cardiac tissue, although troponin and creatine kinase tests are preferred.
== Scientific use == α-Amanitin is a selective inhibitor of RNA polymerase II and III but not I. This mechanism makes it a deadly toxin. α-Amanitin can also be used to determine which types of RNA polymerase are present. This is done by testing the sensitivity of the polymerase in the presence of α-amanitin. RNA polymerase I is insensitive, RNA polymerase II is highly sensitive (inhibited at 1μg/ml), RNA polymerase III is moderately sensitive (inhibited at 10μg/ml), and RNA polymerase IV is slightly sensitive (inhibited at 50μg/ml).
== Prevention == Up to 90% of cardiovascular disease may be preventable if established risk factors are avoided. Medical management of atherosclerosis first involves modification to risk factors–for example, via smoking cessation and diet restrictions. Prevention is generally achieved by eating a healthy diet, exercising, maintaining a normal weight, and not smoking.
== Early life and education == Born in 1953 and raised in Dearborn, Michigan, Tippett is an alumnus of Kalamazoo College and holds a Ph.D. and M.D. from Case Western Reserve University School of Medicine. He studied at the Rockefeller University in New York under Nobel Prize winner Robert Bruce Merrifield, directing his doctoral research efforts toward the metabolic indicators of peptide synthesis. He completed his internship and residency in Internal Medicine at Cleveland Metropolitan General Hospital, and spent 1975-1985 engaged in biochemical research.
Sources: en.wikipedia.org
== Other rhEGFs == Several other products containing recombinant human EGF have been marketed. The potencies of these products can differ by the expression system used, despite all intending to match the structure of human EGF. Instead of measuring by mass, the international unit system from the World Health Organization provides a way to describe the potency-adjusted amount of rhEGF. However, the WHO does not prescribe a specific way of measuring the potency. rhEGF bioassay remains a field in active development.
=== Pre-1970 jury trials === Before they were abolished in 1970, jury trials were conducted to hear capital cases in Singapore since the British colonial era. Based on the verdict of a jury, if a person was found guilty, the judge would convict and impose a penalty to the defendant in accordance to the charge he or she was found guilty of. One notable case in which a person was sentenced to death in a jury trial was the trial of Sunny Ang Soo Suan, who allegedly murdered his girlfriend Jenny Cheok Cheng Kid during a scuba diving trip in 1963. Despite the circumstantial evidence and the absence of the victim's body, the seven-men jury unanimously found Ang guilty of murder and sentenced him to death. Ang was eventually hanged on 6 February 1967 after he lost all his appeals to both the Court of Appeal and the Privy Council, and the failure of his clemency plea to President Yusof Ishak. The first person to be tried before two judges in the High Court and sentenced to death for a capital case was armed robber Teo Cheng Leong, who was found guilty and sentenced in February 1970 for unlawfully discharging a firearm twice when he fired two missed shots at a police officer. Another notable case was the kidnapping and murder of Ong Beang Leck, the son of a rich tycoon. Five men were involved in the abduction and they had murdered Ong after luring him into a rented car on 24 May 1968. Three of the kidnappers were found guilty of murder and sentenced to death in June 1970.
=== Australia and New Zealand === There are 15 recognised specialty medical Colleges in Australia. The majority of these are Australasian Colleges and therefore also oversee New Zealand specialist doctors. These Colleges are:
=== Biotin === Subsequently, with Vincent du Vigneaud, he used the newly developed technique of chromatography that he had learned while a student in Zürich, to isolate and then crystallize biotin. This work began a theme that continued throughout his career of determining the importance of sulfur in biologically active structures. He applied this to peptides as well.
Methyl blue is a chemical compound with the molecular formula C37H27N3Na2O9S3. It is used as a stain in histology, and stains collagen blue in tissue sections. It can be used in some differential staining techniques such as Mallory's trichrome stain and Gömöri trichrome stain, and can be used to mediate electron transfer in microbial fuel cells. Fungal cell walls are also stained by methyl blue. Methyl blue is also available in mixture with water blue, under name Aniline Blue WS, Aniline blue, China blue, or Soluble blue; and in a solution of phenol, glycerol, and lactic acid under the name Lactophenol cotton blue (LPCB), which is used for microscopic visualization of fungi.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.